Confirmatory Clinical Evaluation of Novilase® Laser Therapy for Focal Destruction of Malignant Breast Tumors

Inclusion Criteria:

• Females, aged 18 years and older
• Able to give written informed consent herself
• Definitive pathologic diagnosis by needle core biopsy
• Unifocal malignant tumor (T1a-c, N0-1, M0) that does not exceed 15 mm in longest dimension and measures at least 5 mm away from the skin and chest wall, or can be moved at least 5 mm away from the skin and chest wall by injection of saline or local anesthetic
• No more than 10 mm of calcifications confined to the tumor on imaging
• Tumor is well visualized through ultrasound or x-ray mammography imaging and amenable to image-guidance therapy (i.e., a tumor which is well visualized through imaging can be identified from surrounding breast tissue and does not have margins obscured by other structures or artifacts on the images)
• Tumor is well visualized on MRI
• Subject with mammographic appearance of overall dense parenchymal tissue may be included, as long as a clearly evident marker is present at tumor site
• Tumor with less than 25% intraductal component, as determined by core biopsy
• No clinically significant co-morbidities (e.g., chronic illnesses existing simultaneously with and usually independent of breast cancer) that affect life expectancy
• Subject weight limited to ≤300 lbs. or ≤136 kg
• Subject agrees to comply with standard of care radiation or adjuvant therapy as prescribed by physician

Exclusion Criteria:

• Subject younger than 18 years of age
• Pregnant or breast-feeding
• Tumor poorly visualized by ultrasound or x-ray mammography imaging
• Contraindications to administration of gadolinium-based contrast agent, including: prior allergic reaction to a gadolinium-based contrast agent, moderate to end-stage kidney disease, and/or acute or chronic severe renal insufficiency (Glomerular filtration rate (GFR) <30ml/min/1.73 sq. meters)
• Contraindications to MRI according to site guidelines (e.g., cardiac pacemaker, metallic implants)
• History of severe asthma
• Tumor measuring greater than 15 mm in longest dimension
• Microcalcifications that extend beyond target tumor such that overall longest dimension of target tumor and calcifications is longer than 15 mm.
• Advanced stage breast cancer
• Tumors that are lobular neoplasm, metastatic carcinoma to breast, sarcoma, Phyllodes tumor, or Paget's disease
• Tumor with only DCIS with microinvasion
• Extensive intraductal component in lesion (i.e., >25%) as determined by core biopsy
• Subject who is known to be BRCA positive
• Tumor that is ER/PR/HER2 negative (TNBC)
• Inability to lie in prone or supine position for one hour
• Subject who is currently participating in another investigational treatment, device or drug study through follow up that would interfere with this trial
• Subject who falls into high risk group on Caprini Risk Assessment for deep vein thrombosis (DVT) and requires Lovenox (Enoxaparin)
• Subject without a definitive HER2 test according to ASCO/CAP guidelines